Detalhe da pesquisa
1.
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Am J Hematol
; 97(4): 421-430, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015312
2.
Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Br J Haematol
; 193(5): 915-921, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33782950
3.
Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study.
Eur J Haematol
; 107(6): 617-623, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34418168
4.
Neurosurgical untethering with or without syrinx drainage results in high patient satisfaction and favorable clinical outcome in post-traumatic myelopathy patients.
Spinal Cord
; 56(9): 873-882, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29588484
5.
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 781-787, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38278960
6.
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Leukemia
; 38(4): 925, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38418611
7.
The impact of Covid-19 in patients with chronic myeloid leukemia-a nationwide population-based study.
Leukemia
; 37(5): 1156-1159, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37037908